Longeveron (LGVN)
NASDAQ:LGVN
Want to see LGVN full AI Analyst Report?
Top Page
Longeveron
(NASDAQ:LGVN)
Select Model
Select Model
Rating:50Neutral
Price Target:
$0.87
▼(-21.36% Downside)
Action:ReiteratedDate:04/11/26
The score is held back primarily by weak financial performance (persistent losses and cash burn with elevated dilution/financing risk). Technicals are supportive with price above key moving averages and positive MACD, while valuation is constrained by negative earnings and no dividend. Earnings call adds medium support due to defined clinical catalysts and improved runway, tempered by declining revenue and rising expenses.
Positive Factors
Pivotal HLHS Readout Imminent
Completing enrollment and targeting a Q3 2026 topline readout materially shortens the clinical timeline for laromestrocel. A positive pivotal result could enable BLA preparation, accelerate regulatory milestones and meaningfully de‑risk commercialization prospects and partner interest over the next 2–4 years.
Negative Factors
Persistent Cash Burn & Losses
Sustained negative operating and free cash flow signals ongoing cash burn that historically tracks accounting losses. This structural deficit forces repeated capital raises, constrains discretionary R&D or commercial investment, and increases dilution risk unless a major regulatory or partnering event materializes.
Read all positive and negative factors
Positive Factors
Negative Factors
Pivotal HLHS Readout Imminent
Completing enrollment and targeting a Q3 2026 topline readout materially shortens the clinical timeline for laromestrocel. A positive pivotal result could enable BLA preparation, accelerate regulatory milestones and meaningfully de‑risk commercialization prospects and partner interest over the next 2–4 years.
Read all positive factors
Longeveron (LGVN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$20.14M
Dividend YieldN/A
Average Volume (3M)473.11K
Price to Earnings (P/E)―
Beta (1Y)1.58
Revenue Growth-49.87%
EPS Growth67.92%
CountryUS
Employees25
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.23
Shares Outstanding21,783,749
10 Day Avg. Volume706,553
30 Day Avg. Volume473,105
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.57
Price to Sales (P/S)7.42
P/FCF Ratio-0.47
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue13.62
Enterprise Value/Gross Profit31.17
Enterprise Value/Ebitda-0.76
Forecast
1Y Price Target
$2.00Price Target Upside81.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.84
Revenue Forecast (FY)$715.67K
Longeveron Business Overview & Revenue Model
Company Description
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from ...
How the Company Makes Money
null...
Longeveron Key Performance Indicators (KPIs)
Any
Revenue by Segment
Shows how Longeveron’s revenue is split across sources such as clinical trial services, grants, collaboration or licensing payments, and any product or service sales. A mix weighted toward grants and milestone payments means revenue can be lumpy and dependent on partnership timing; growing product or recurring revenue would indicate progress toward commercialization, steadier cash flow, and lower execution risk for investors.
Shows how Longeveron’s revenue is split across sources such as clinical trial services, grants, collaboration or licensing payments, and any product or service sales. A mix weighted toward grants and milestone payments means revenue can be lumpy and dependent on partnership timing; growing product or recurring revenue would indicate progress toward commercialization, steadier cash flow, and lower execution risk for investors.
Data provided by:
The Fly
The FlyLongeveron Earnings Call Summary
Earnings Call Date:Mar 17, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 08, 2026
Earnings Call Sentiment Neutral
The call balanced meaningful clinical and strategic progress (pivotal HLHS readout expected in Q3 2026, IND effectiveness for PDCM, publications/patents, and a $15.9M financing improving runway) against material near-term financial and operational challenges (50% revenue decline, 41% larger net loss, rising R&D/G&A spend, low year-end cash of $4.7M and reliance on additional financing or PRV monetization). While the company has clear catalysts and credible scientific validation, its liquidity profile and widened losses temper the outlook in the near term.Positive Updates
Completed Enrollment of Pivotal HLHS Trial (ELPIS II) and Near-Term Readout
ELPIS II enrollment of 40 patients was completed in June 2025; top-line pivotal Phase IIb results are anticipated in Q3 2026 and, if positive, could support preparation of the company's first BLA and potentially accelerate regulatory approval.
Negative Updates
Sharp Revenue Decline
Total revenues fell to $1.2 million for the year ended December 31, 2025 from $2.4 million in 2024, a decrease of $1.2 million or 50%, driven by lower participant demand for the Bahamas registry trial and reduced third-party contract manufacturing demand.
Read all updates
Q4-2025 Updates
Positive
Negative
Completed Enrollment of Pivotal HLHS Trial (ELPIS II) and Near-Term Readout
ELPIS II enrollment of 40 patients was completed in June 2025; top-line pivotal Phase IIb results are anticipated in Q3 2026 and, if positive, could support preparation of the company's first BLA and potentially accelerate regulatory approval.
Read all positive updates
Company Guidance
The company provided clear near‑term financial and clinical guidance: as of December 31, 2025 cash and cash equivalents were $4.7M with ~$1.4M in working capital, and after a March 11 private placement that raised approximately $15.9M (with an initial $15M noted from key investors and a potential second tranche of $15M upon milestones) management expects runway into Q4 2026; 2025 revenue was $1.2M (clinical trial $1.0M; contract manufacturing $0.2M) versus $2.4M in 2024 (a 50% decline), G&A was ~$12M vs $10.3M (+17%), R&D was ~$12M vs $8.1M (+48%), and net loss widened to ~$22.7M from $16M (+41%); clinically, the pivotal ELPIS II HLHS trial (40 patients enrolled, enrollment completed June 2025) has topline results expected in Q3 2026 and, if positive, the company plans BLA preparation with potential rolling submission/priority review targeting a 2027 filing, HLHS has rare pediatric disease designation (making it PRV‑eligible) and the company’s financing agreement gives investors 50% of any HLHS PRV proceeds (PRVs have sold for $150M–$205M since Aug 2024); the PDCM IND became effective July 2025 with a planned global single pivotal Phase II registrational study of ~70 patients (one‑year study, dosing every 3 months) aiming for feasibility in 2026 and initiation in 2027, while Alzheimer’s and frailty programs will pursue strategic partnerships.Longeveron Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.20M | 2.39M | 709.00K | 1.22M | 1.31M |
| Gross Profit | 803.00K | 1.88M | 221.00K | 497.00K | 590.00K |
| EBITDA | -22.06M | -15.56M | -20.08M | -17.15M | -16.13M |
| Net Income | -22.70M | -15.97M | -21.41M | -18.84M | -17.05M |
Balance Sheet | |||||
| Total Assets | 10.26M | 25.56M | 12.08M | 27.41M | 42.77M |
| Cash, Cash Equivalents and Short-Term Investments | 4.66M | 19.23M | 5.36M | 19.66M | 35.04M |
| Total Debt | 824.00K | 1.45M | 2.04M | 2.60M | 3.14M |
| Total Liabilities | 4.59M | 3.67M | 5.34M | 6.91M | 5.31M |
| Stockholders Equity | 5.67M | 21.89M | 6.74M | 20.50M | 37.45M |
Cash Flow | |||||
| Free Cash Flow | -18.89M | -14.86M | -19.30M | -14.82M | -10.95M |
| Operating Cash Flow | -18.64M | -13.87M | -19.00M | -13.97M | -9.64M |
| Investing Cash Flow | -595.00K | -640.00K | 8.19M | -677.00K | -10.70M |
| Financing Cash Flow | 4.67M | 28.79M | 5.26M | -509.00K | 45.17M |
Longeveron Technical Analysis
Positive
1.10
Price Trends
0.81
Positive
0.69
Positive
0.84
Positive
Market Momentum
0.09
Positive
59.83
Neutral
31.14
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LGVN, the sentiment is Positive. The current price of 1.1 is above the 20-day moving average (MA) of 1.05, above the 50-day MA of 0.81, and above the 200-day MA of 0.84, indicating a bullish trend. The MACD of 0.09 indicates Positive momentum. The RSI at 59.83 is Neutral, neither overbought nor oversold. The STOCH value of 31.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LGVN.
Longeveron Risk Analysis
Longeveron disclosed 91 risk factors in its most recent earnings report. Longeveron reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Longeveron Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $141.28M | -1.26 | -55.75% | ― | ― | 39.03% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $20.14M | -0.39 | -119.92% | ― | -49.87% | 67.92% | |
47 Neutral | $7.05M | -0.55 | -257.81% | ― | ― | 82.64% | |
46 Neutral | $58.55M | -5.32 | -71.26% | ― | -20.00% | 62.69% | |
43 Neutral | $10.50M | -1.16 | -89.92% | ― | ― | 58.63% | |
42 Neutral | $4.60M | -0.54 | -1292.87% | ― | ― | -30.18% |
* Healthcare Sector Average
LGVN
Longeveron
0.85
-0.71
-45.51%
IBIO
Ibio
1.69
0.66
64.08%
EDSA
Edesa Biotech
18.28
15.90
667.86%
CMMB
Chemomab Therapeutics
1.47
-4.01
-73.18%
PCSA
Processa Pharmaceuticals
2.70
-3.55
-56.80%
FBLG
FibroBiologics, Inc.
1.32
-19.08
-93.53%
Longeveron Corporate Events
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and Financing
Longeveron Restores Executive Pay After Recent Financing
Positive
Apr 10, 2026
In February 2026, Longeveron implemented a temporary 25% to 50% reduction in compensation and fees for its executive officers and Board as part of a broader review of its cash runway and cost structure. Following the closing of a financing transac...
Delistings and Listing ChangesRegulatory Filings and Compliance
Longeveron Receives Extended Nasdaq Compliance Grace Period
Negative
Mar 25, 2026
On September 22, 2025, Longeveron Inc. disclosed it had fallen out of compliance with Nasdaq’s $1.00 minimum bid price rule after its Class A common stock traded below that threshold for thirty consecutive business days, triggering an initia...
Shareholder MeetingsStock Split
Longeveron Cancels Special Meeting, Reschedules Reverse Split Vote
Neutral
Mar 24, 2026
On March 23, 2026, Longeveron Inc. cancelled a special meeting of stockholders that had been scheduled to take place in 2026, halting the originally planned forum for certain shareholder votes. The company now plans to move the previously proposed...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Longeveron Announces $30 Million Private Placement Financing
Positive
Mar 12, 2026
On March 10, 2026, Longeveron entered into a securities purchase agreement for a private placement of up to approximately $30 million, led by Coastlands Capital with participation from Janus Henderson Investors and other healthcare funds, priced a...
Business Operations and StrategyExecutive/Board Changes
Longeveron Appoints New CEO Amid Cost-Cutting Initiatives
Neutral
Feb 13, 2026
On February 9, 2026, interim CEO Than Powell resigned from his temporary role at Longeveron but remained with the company in business development, as the board appointed veteran biotech executive Stephen H. Willard as permanent CEO effective Febru...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.